CODEXIS, INC.
Datakwaliteit: 100%
CDXS
NASDAQ
Manufacturing
Chemicals
€ 2,24
▼
€ 0,16
(-6,67%)
Marktkapitalisatie: 209,91 M
Prijs
€ 2,31
Marktkapitalisatie
209,91 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Revenue declined -9,46% annually over 5 years
Negative free cash flow of -23,85 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 28,07%
Capital efficient — spends only 6,35% of revenue on capex
Groei
Revenue Growth (5Y)
-9,46%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)18,61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-93,39%
Onder sectorgemiddelde (-54,01%)
ROIC-28,86%
Net Margin-62,47%
Op. Margin-59,30%
Veiligheid
Debt / Equity
1,03
Boven sectorgemiddelde (0,30)
Current Ratio4,12
Interest CoverageN/A
Waardering
PE (TTM|NTM)
-4,77 | -10,18
Onder sectorgemiddelde (-1,49)
P/B Ratio5,45
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1385 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1385 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -4,8 | -1,5 |
| P/B | 5,5 | 1,6 |
| ROE % | -93,4 | -54,0 |
| Net Margin % | -62,5 | -41,5 |
| Rev Growth 5Y % | -9,5 | 1,8 |
| D/E | 1,0 | 0,3 |
Koersdoel Analisten
6 analisten
Buy
Huidig
€ 2,24
Koersdoel
€ 6,58
€ 2,00
€ 7,00
€ 11,00
Vooruitzicht
Forward K/W
-10,18
Forward WPA
-€ 0,22
Omzet Sch.
89,87 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
-€ 0,22
-€ 0,38 – -€ 0,06
|
89,87 M | 2 |
| FY2026 |
-€ 0,32
-€ 0,46 – -€ 0,21
|
74,34 M | 3 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
-€ 0,11
-€ 0,14 – -€ 0,07
|
16,61 M | 2 |
| 2026 Q1 |
-€ 0,11
-€ 0,13 – -€ 0,08
|
14,44 M | 2 |
Winstverassingen
Laatste 4 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | -€ 0,04 | € 0,14 | +508,6% |
| Q32025 | -€ 0,13 | -€ 0,22 | -73,7% |
| Q22025 | -€ 0,15 | -€ 0,16 | -6,7% |
| Q12025 | -€ 0,21 | -€ 0,25 | -20,5% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 18,61% | Revenue Growth (3Y) | 0,17% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -9,46% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 70,39 M | Net Income (TTM) | -43,97 M |
| ROE | -93,39% | ROA | -33,54% |
| Gross Margin | N/A | Operating Margin | -59,30% |
| Net Margin | -62,47% | Free Cash Flow (TTM) | -23,85 M |
| ROIC | -28,86% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,03 | Current Ratio | 4,12 |
| Interest Coverage | N/A | Asset Turnover | 0,54 |
| Working Capital | 57,72 M | Tangible Book Value | 36,08 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -4,77 | Forward P/E | -10,18 |
| P/B Ratio | 5,45 | P/S Ratio | 2,98 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 2,34 | Fwd Earnings Yield | N/A |
| FCF Yield | -11,36% | ||
| Market Cap | 209,91 M | Enterprise Value | 224,29 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,50 | Revenue / Share | 0,77 |
| FCF / Share | -0,26 | OCF / Share | -0,21 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 6,35% | FCF Conversion | 54,23% |
| SBC-Adj. FCF | -33,98 M | Growth Momentum | 28,07 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 70,39 M | 59,35 M | 70,14 M | 138,59 M | 104,75 M |
| Net Income | -43,97 M | -65,28 M | -76,24 M | -33,59 M | -21,28 M |
| EPS (Diluted) | -0,50 | -0,89 | -1,12 | -0,51 | -0,33 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -41,74 M | -58,52 M | -68,07 M | -34,88 M | -22,70 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 52,31 M | 46,26 M | 58,89 M | 80,10 M | 55,92 M |
| SG&A Expenses | 47,07 M | 55,15 M | 53,25 M | 52,17 M | 49,32 M |
| D&A | 5,25 M | 4,95 M | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 47.000,0 | 34.000,0 | 69.000,0 | 276.000,0 | 189.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 147,80 M | 149,01 M | 136,56 M | 250,39 M | 246,38 M |
| Total Liabilities | 97,27 M | 82,08 M | 49,95 M | 105,60 M | 81,99 M |
| Shareholders' Equity | 50,53 M | 66,93 M | 86,62 M | 144,80 M | 164,39 M |
| Total Debt | 40,11 M | 28,91 M | — | — | — |
| Cash & Equivalents | 50,79 M | 19,26 M | 65,12 M | 113,98 M | 116,80 M |
| Current Assets | 96,82 M | 98,77 M | 93,47 M | 162,89 M | 161,89 M |
| Current Liabilities | 25,32 M | 23,65 M | 35,83 M | 49,07 M | 33,37 M |
{"event":"ticker_viewed","properties":{"ticker":"CDXS","listing_kind":"stock","pathname":"/stocks/cdxs","exchange":"NASDAQ","country":"US"}}